The Beckman Coulter Access DxI AFP method is used. Results obtained with different assay methods or kits cannot be used interchangeably. AFP is a valuable aid in the management of nonseminomatous testicular cancer patients when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased AFP concentrations have also been observed in ataxia telangiectasia, hereditary tyrosinemia, primary hepatocellular carcinoma, teratocarcinoma, gastrointestinal tract cancers with and without liver metastases, and in benign hepatic conditions such as acute viral hepatitis, chronic active hepatitis, and cirrhosis. The result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result is not interpretable as a tumor marker in pregnant females.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note

CPT Code(s)

86316

Components

Component Test Code*

Component Chart Name

LOINC

0020729

Alpha Fetoprotein, CSF (Tumor Marker)

1833-3

* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Provide Feedback on ARUP Lab Test Directory

*I want to provide feedback regarding:Please select a feedback type

*Test Number:Please enter a test name or number

Please type your message. If you are reporting a problem, please indicate what you
were trying to do when the problem occurred, what you expected to happen, and what actually happened:*CommentPlease enter a comment